Letter to the May 5 Journal of the American Medical Association from FDA's Stuart Nightingale, Peter Rheinstein and James Morrison says agency concludes "no bioequivalence problem with the generic product could be confirmed." The FDA letter responds to Sept. 4, 1987 article entitled "Increased Seizure Frequency with Generic Primidone," which detailed poor response of one patient who had been switched from Wyeth-Ayerst's Mysoline to the generic. An accompanying letter from Bolar points out that Cleveland Clinic incident "clearly indicated that there was no evidence of generic failure since this patient responded poorly" to both versions of the drug," and notes that Bolar sales of product were negatively impacted by article.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.